ReviewTechnology in cancer research & treatment2018
Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.
Review in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 168 citations in OpenAlex.
- Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy.International journal of molecular sciences · 2026Review
- Photodynamic Therapy for Keratinocytic Precancerous Lesions and Non-Melanoma Skin Cancer: A Narrative Review.International journal of molecular sciences · 2026Review
- Article
- Photodynamic therapy with zinc phthalocyanine suppresses immune checkpoints in human melanoma cells.Lasers in medical science · 2026Article
- The interplay between autophagy and immunogenic cell death: nanomaterial-based strategies for cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Non-surgical Synergistic Interventions for the Treatment of Skin Cancer.Current pharmaceutical design · 2026Review
- Peptide-modified phase-transition nanoparticles co-deliver FTO siRNA and Ce6 for sonodynamic metabolism-immunotherapy of melanoma.Journal of nanobiotechnology · 2025Article
- The examination of in vitro photosensitizing efficacy of aloe-emodin loaded liposome following photodynamic therapy on melanoma cell lines.Scientific reports · 2025Article
- Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges.Pharmaceutics · 2025Review
- Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.Journal of experimental & clinical cancer research : CR · 2025Review
- Iron oxide nanoparticles empowering melanoma therapy: advances in multifunctional platform research.Frontiers in bioengineering and biotechnology · 2025Review
- Oxidative State in Cutaneous Melanoma Progression: A Question of Balance.Antioxidants (Basel, Switzerland) · 2024Review
- Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications.Heliyon · 2024Review
- Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights.RSC advances · 2024Review
- Review
- Mesoporous silica coated spicules for photodynamic therapy of metastatic melanoma.Journal of nanobiotechnology · 2024Article
- A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.ACS omega · 2024Review
- Advancements in skin cancer treatment: focus on photodynamic therapy: a review.American journal of cancer research · 2024Review
- Applications and challenges of photodynamic therapy in the treatment of skin malignancies.Frontiers in pharmacology · 2024Review
- Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment.NPJ biofilms and microbiomes · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article is based on specifically targeted nanoparticles that have been used in the treatment of melanoma. According to the Skin Cancer Foundation, within 2017 an estimated 9730 people will die due to invasive melanoma. Conventional treatments for nonmalignant melanoma include surgery, chemotherapy, and radiation. For the treatment of metastatic melanoma, 3 therapeutic agents have been approved by the Food and Drug Administration: dacarbazine, recombinant interferon α-2b, and high-dose interleukin 2. Photodynamic therapy is an alternative therapy that activates a photosensitizer at a specific wavelength forming reactive oxygen species which in turn induces cell death; it is noninvasive with far less side effects when compared to conventional treatments. Nanoparticles are generally conjugated to photosynthetic drugs, since they are biocompatible, stabile, and durable, as well as have a high loading capacity, which improve either passive or active photosensitizer drug delivery to targeted cells. Therefore, various photosynthetic drugs and nanoparticle drug delivery systems specifically targeted for melanoma were analyzed in this review article in relation to either their passive or their active cellular uptake mechanisms in order to deduce the efficacy of photodynamic therapy treatment for metastatic melanoma which currently remains ongoing. The overall findings from this review concluded that no current photodynamic therapy studies have been performed in relation to active nanoparticle platform photosensitizer drug carrier systems for the treatment of metastatic melanoma, and so this type of research requires further investigation into developing a more efficient active nano-photosensitizer carrier smart drug that can be conjugated to specific cell surface receptors and combinative monoclonal antibodies so that a further enhanced and more efficient form of targeted photodynamic therapy for the treatment of metastatic melanoma can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.